Puma Biotechnology, Inc. (PBYI) Vs. Lilis Energy, Inc. (LLEX): Which Is Slowing Down?

2 analysts out of 10 Wall Street brokerage firms rate Puma Biotechnology, Inc. (NASDAQ:PBYI) as a Buy, while 3 see it as a Sell. The rest 5 describe it as a Hold. PBYI stock traded higher to an intra-day high of $42.124. At one point in session, its potential discontinued and the price was down to lows at $39.07. Analysts have set PBYI’s consensus price at $43.88, effectively giving it a 11.74% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $70 (up 78.25% from current price levels).

It is expected that in Mar 2019 quarter PBYI will have an EPS of $-0.69, suggesting a -6.15% growth. For Jun 2019 is projected at $-0.59. It means that there could be a 49.57% growth in the quarter. Yearly earnings are expected to rise by 32.44% to about $-2.02. As for the coming year, growth will be about 91.09%, lifting earnings to $-0.18. RSI after the last trading period was 67.05. PBYI recorded a change of 2.88% over the past week and returned 66.96% over the last three months while the PBYI stock’s monthly performance revealed a shift in price of 45.61%. The year to date (YTD) performance stands at 92.97%, and the bi-yearly performance specified an activity trend of -16.8% while the shares have moved -46.79% for the past 12 months.

Puma Biotechnology, Inc. (PBYI) currently trades at $39.27, which is lower by -6.5% its previous price. It has a total of 38.47 million outstanding shares, with an ATR of around 2.21. The company’s stock volume dropped to 1.09 million, worse than 1.17 million that represents its 50-day average. A 5-day increase of about 2.88% in its price means PBYI is now 92.97% higher on year-to-date. The shares have surrendered $43366.73 since its $76.45 52-week high price recorded on 16th of March 2018. Overall, it has seen a growth rate of -46.79 over the last 12 months. The current price per share is $21.67 above the 52 week low of $17.60 set on 2nd of November 2018.

Puma Biotechnology, Inc. (NASDAQ:PBYI)’s EPS was $-0.8 as reported for the December quarter. In comparison, the same quarter a year ago had an EPS of $-1.71. That means that its growth in general now stands at -53%. Therefore, a prediction of $-0.77 given by the analysts brought a positive surprise of 4%. PBYI Dec 19 quarter revenue was $71.1 million, compared to $21.6 million recorded in same quarter last year, giving it a 229% growth rate. The company’s $49.5 million revenue growth that quarter surprised Wall Street and investors will need to consider this as they assess the stock.

Lilis Energy, Inc. (NYSE:LLEX) shares depreciated -5.23% over the last trading period, taking overall 5-day performance up to -18.08%. LLEX’s price now at $1.45 is weaker than the 50-day average of $1.8. Getting the trading period increased to 200 days, the stock price was seen at $3.52 on average. The general public currently hold control of a total of 47.95 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 80.63 million. The company’s management holds a total of 19.1%, while institutional investors hold about 0% of the remaining shares. LLEX share price finished last trade -20.96% below its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -59.03%, while closing the session with -19.21% distance from 50 day simple moving average.

Lilis Energy, Inc. (LLEX) shares were last observed trading -76.98% down since May 30, 2018 when the peak of $6.3 was hit. Last month’s price growth of -20.77% puts LLEX performance for the year now at 5.84%. Consequently, the shares price is trending higher by 36.79%, a 52-week worst price since Dec. 27, 2018. However, it is losing value with -73% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $1.3 and $1.38. The immediate resistance area is now $1.54 Williams’s %R (14) for LLEX moved to 90.16 while the stochastic %K points at 13.33.

LLEX’s beta is 0.72; meaning investors could reap lower returns, although it also poses lower risks. The company allocated $-1.3 per share from its yearly profit to its outstanding shares. Its last reported revenue is $18.86 million, which was 141% versus $7.83 million in the corresponding quarter last year. The EPS for Sep 19 quarter came in at $-0.06 compared to $-0.74 in the year-ago quarter and had represented -92% year-over-year earnings per share growth. LLEX’s ROA is -3.6%, lower than the 4.98% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 8.05%.

Estimated quarterly earnings for Lilis Energy, Inc. (NYSE:LLEX) are around $-0.07 per share in three months through December with $-0.1 also the estimate for March quarter of the fiscal year. It means the growth is estimated at 92.55% and 33.33%, respectively. Analysts estimate full-year growth to be 75.9%, the target being $-0.47 a share. The upcoming year will see an increase in growth by percentage to 34.04%, more likely to see it hit the $-0.31 per share. The firm’s current profit margin over the past 12 months is -25.1%. LLEX ranks lower in comparison to an average of 17.83% for industry peers; while the average for the sector is 76.73%.